Mycoplasma Testing Market Report 2025 (Global Edition)

Global Mycoplasma Testing Market Report 2025 Market Size Split by Product (Instruments, Kits and Reagents, Services), by Technology (PCR, ELISA, Microbial Culture Techniques, Enzymatic Methods), by Ap...

Mycoplasma Testing Market Report Description

We have various report editions of Mycoplasma Testing Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Mycoplasma Testing Market Insights Video

Competitive Landscape of the Mycoplasma Testing Market

The Mycoplasma Testing Market is competitive, featuring key players like Thermo Fisher Scientific, Charles River Laboratories, and Lonza Group. Companies compete on technology innovation, product accuracy, and regulatory compliance. Major players differentiate themselves with advanced testing methods, such as PCR and next-generation sequencing. Strategic partnerships, mergers, and acquisitions are common as firms aim to expand their market presence and technological capabilities. The focus is on meeting stringent regulatory standards and addressing growing demand for contamination-free biopharmaceutical production.

May 2022: Abbott obtained clearance from the United States Food and Drug Administration for its Alinity m STI Assay. This test is designed to simultaneously identify and distinguish four prevalent sexually transmitted infections (STIs), including Mycoplasma genitalium (MG). (Source: https://abbott.mediaroom.com/2022-05-04-Abbott-Obtains-FDA-Clearance-for-First-Test-that-Simultaneously-Detects-Four-Common-Sexually-Transmitted-Infections-STIs-as-Cases-are-on-the-Rise) October 2022: Performer Availability Screening Service, Inc. (PASS) has teamed up with Spankchain to initiate a screening and treatment program for Mycoplasma genitalium infections within the Las Vegas performer community. This service will be provided at no cost to up to 1,000 performers. (Source: https://www.passcertified.org/news/pass-launches-no-cost-mgen-testing) September 2022: Infinity Laboratories has broadened its offerings by introducing Mycoplasma testing services. The adoption of strategies such as expansion, partnerships, and acquisitions by leading market players is expected to enhance their capabilities and contribute to overall market growth. (Source: https://infinitylaboratories.com/services/testing/microbiology-testing/)

Top Companies Market Share in Mycoplasma Testing Industry: (In no particular order of Rank)

• Thermo Fisher Scientific Inc.
• Charles River Laboratories International
• Inc.
• Lonza Group Ltd.
• Merck KGaA (MilliporeSigma in the US and Canada)
• Becton
• Dickinson and Company (BD)
• Bio-Rad Laboratories
• Inc.
• Agilent Technologies
• Inc.
• Horizon Discovery Group plc
• Genetic ID NA
• Inc.
• Euformatics
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Mycoplasma Testing Market

Which Region Dominates the Mycoplasma Testing Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40% of the global revenue due to the region's advanced healthcare infrastructure, strong presence of biopharmaceutical and biotechnology companies, and rigorous regulatory requirements. High investment in research and development, coupled with increased production of biologics and cell therapies, drives demand for mycoplasma testing. Additionally, North America's focus on ensuring product safety and efficacy through stringent testing standards contributes to its dominant market position.

Which Region is Expanding at the Fastest CAGR?

The Asia Pacific region is growing at the fastest CAGR in the Mycoplasma Testing Market due to rapid expansion in biopharmaceutical and biotechnology industries, increasing research and development activities, and rising healthcare investments. The growing prevalence of chronic diseases and a burgeoning demand for biologics and cell-based therapies drive the need for rigorous contamination testing. Additionally, improving healthcare infrastructure and regulatory advancements in the region contribute to the accelerated market growth.

The current report Scope analyzes Mycoplasma Testing Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Mycoplasma Testing Market

According to Cognitive Market Research, the global Mycoplasma Testing market size was estimated at USD 945.6 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 378.24 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.4% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Mycoplasma Testing market with a market size of USD 298.43 million in 2024 and is projected to grow at a CAGR of 12.2% during the forecast period. The nation's strong presence of pharmaceutical and biotechnology companies, increased research and development activities, and stringent regulatory requirements for biopharmaceutical production is driving the Mycoplasma Testing market.
• The Canada Mycoplasma Testing market had a market share of USD 45.39 million in 2024 and is projected to grow at a CAGR of 13.2% during the forecast period. Canada's increasing investment in cell culture and biologics manufacturing is driving the Mycoplasma Testing market.
• The Mexico Mycoplasma Testing market is projected to witness growth at a CAGR of 12.9% during the forecast period, with a market size of USD 34.42 million in 2024.

Europe Mycoplasma Testing Market

According to Cognitive Market Research, the global Mycoplasma Testing market size was estimated at USD 945.6 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 283.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.7% from 2024 to 2031.

• The United Kingdom Mycoplasma Testing market had a market share of USD 47.66 million in 2024 and is projected to grow at a CAGR of 13.5% during the forecast period. In the UK, Mycoplasma Testing sales witness an upswing due to strong focus on biopharmaceutical and biotechnology research, along with stringent regulatory standards for cell culture and biologics manufacturing.
• The France Mycoplasma Testing market is projected to witness growth at a CAGR of 11.9% during the forecast period, with a market size of USD 26.10 million in 2024.
• According to Cognitive Market Research, the German Mycoplasma Testing market size was valued at USD 56.17 million in 2024 and is projected to grow at a CAGR of 12.9% during the forecast period. In Germany, Mycoplasma Testing surged due to the presence of major market players.
• The Italy Mycoplasma Testing market is projected to witness growth at a CAGR of 12.1% during the forecast period, with a market size of USD 24.40 million in 2024.
• The Russia Mycoplasma Testing market is projected to witness growth at a CAGR of 11.7% during the forecast period, with a market size of USD 43.97 million in 2024.
• The Spain Mycoplasma Testing market is projected to witness growth at a CAGR of 11.8% during the forecast period with a market size of USD 23.26 million in 2024
• The Luxembourg Mycoplasma Testing market is projected to witness growth at a CAGR of 12.8% during the forecast period, with a market size of USD 8.79 million in 2024.
• The Portugal Mycoplasma Testing market is projected to witness growth at a CAGR of 12.5% during the forecast period, with a market size of USD 5.96 million in 2024.
• The Greece Mycoplasma Testing market is projected to witness growth at a CAGR of 13.0% during the forecast period, with a market size of USD 3.40 million in 2024.
• Rest of Europe's Mycoplasma Testing market is projected to witness growth at a CAGR of 11.4% during the forecast period, with a market size of USD 43.97 million in 2024.

Asia Pacific Mycoplasma Testing Market

According to Cognitive Market Research, the global Mycoplasma Testing market size was estimated at USD 945.6 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 217.49 million in 2024 and will grow at a compound annual growth rate (CAGR) of 16.2% from 2024 to 2031.

• According to Cognitive Market Research, the China Mycoplasma Testing market size was valued at USD 97.87 million in 2024 and is projected to grow at a CAGR of 15.7% during the forecast period. Mycoplasma Testing surged in China due to expanding biotechnology and pharmaceutical industries, driven by increasing investment in research and development.
• The Japan Mycoplasma Testing market is projected to witness growth at a CAGR of 14.7% during the forecast period, with a market size of USD 30.01 million in 2024.
• The India Mycoplasma Testing market had a market share of USD 26.10 million in 2024 and is projected to grow at a CAGR of 18.0% during the forecast period. India's development of healthcare infrastructure is driving the Mycoplasma Testing market.
• The South Korean Mycoplasma Testing market is projected to witness growth at a CAGR of 15.3% during the forecast period, with a market size of USD 21.75 million in 2024.
• The Australian Mycoplasma Testing market is projected to witness growth at a CAGR of 15.9% during the forecast period, with a market size of USD 11.31 million in 2024.
• The South East Asia Mycoplasma Testing market is projected to witness growth at a CAGR of 17.2% during the forecast period, with a market size of USD 15.01 million in 2024.
• The Rest of Asia Pacific Mycoplasma Testing market is projected to witness growth at a CAGR of 16.0% during the forecast period, with a market size of USD 15.44 million in 2024.

South America Mycoplasma Testing Market

According to Cognitive Market Research, the global Mycoplasma Testing market size was estimated at USD 945.6 Million, out of which the Latin America market has more than 5% share of the global revenue with a market size of USD 47.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.6% from 2024 to 2031. .

• According to Cognitive Market Research, the Brazil Mycoplasma Testing market size was valued at USD 20.24 million in 2024 and is projected to grow at a CAGR of 14.2% during the forecast period. Mycoplasma Testings flourished in Brazil due to growing demand for biologics.
• Argentina's Mycoplasma Testing market had a market share of USD 7.94 million in 2024 and is projected to grow at a CAGR of 14.5% during the forecast period. Argentina's establishment of local manufacturing facilities augment the demand.
• Colombia Mycoplasma Testing market is projected to witness growth at a CAGR of 13.4% during the forecast period, with a market size of USD 4.21 million in 2024.
• Peru Mycoplasma Testing market is projected to witness growth at a CAGR of 13.8% during the forecast period, with a market size of USD 3.88 million in 2024.
• Chile Mycoplasma Testing market is projected to witness growth at a CAGR of 13.9% during the forecast period, with a market size of USD 3.40 million in 2024.
• The Rest of Latin America's Mycoplasma Testing market is projected to witness growth at a CAGR of 12.7% during the forecast period, with a market size of USD 7.61 million in 2024.

Middle East Mycoplasma Testing Market

According to Cognitive Market Research, the global Mycoplasma Testing market size was estimated at USD 945.6 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 18.91 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.9% from 2024 to 2031..

• The GCC Countries Mycoplasma Testing market is projected to witness growth at a CAGR of 14.7% during the forecast period, with a market size of USD 8.09 million in 2024. Mycoplasma Testing sales flourish due to the presence of major market players.
• The Egypt Mycoplasma Testing market is projected to witness growth at a CAGR of 14.2% during the forecast period, with a market size of USD 1.99 million in 2024.
• The South Africa Mycoplasma Testing market is projected to witness growth at a CAGR of 14.9% during the forecast period, with a market size of USD 2.99 million in 2024. Mycoplasma Testing sales flourish in South Africa due to increasing investments in biotechnology and pharmaceutical industries, particularly in Gulf countries.
• The Turkey Mycoplasma Testing market is projected to witness growth at a CAGR of 13.4% during the forecast period, with a market size of USD 1.63 million in 2024.
• The Nigeria Mycoplasma Testing market is projected to witness growth at a CAGR of 13.0% during the forecast period, with a market size of USD 1.99 million in 2024.
• The Rest of MEA Mycoplasma Testing market is projected to witness growth at a CAGR of 12.9% during the forecast period, with a market size of USD 2.23 million in 2024.

Mycoplasma Testing Market Analysis

Mycoplasma Testing Market Product Segment Analysis

According to Cognitive Market Research, Instruments stands out as the dominant category. The Instruments product segment holds the largest market share in the Mycoplasma Testing Market due to their essential role in performing accurate and reliable tests. Advanced instruments, such as PCR machines and automated detection systems, are crucial for detecting mycoplasma contamination with high precision. Their ability to provide rapid results and support high-throughput testing drives demand. Additionally, continuous advancements in technology and the need for stringent quality control in biopharmaceutical production contribute to the dominance of this segment.

The Kits and Reagents product segment is growing at the highest CAGR in the Mycoplasma Testing Market due to the increasing demand for user-friendly and efficient testing solutions. These products offer convenience, ease of use, and cost-effectiveness for laboratories and research facilities. Advances in reagent formulations and the development of more sensitive and accurate testing kits drive their adoption. Additionally, their role in supporting various testing applications, including routine quality control and research, contributes to their rapid growth.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Mycoplasma Testing Industry. Request a Free Sample PDF!

Mycoplasma Testing Market Technology Segment Analysis

According to Cognitive Market Research, the dominant category is PCR. PCR technology holds the largest market share in the Mycoplasma Testing Market due to its high sensitivity, specificity, and rapid detection capabilities. PCR's ability to amplify and detect even low levels of mycoplasma DNA makes it an essential tool for ensuring contamination-free biopharmaceuticals and cell cultures. Its established use in research and clinical settings, combined with continuous advancements improving accuracy and speed, further cements PCR's dominant position in the market.

ELISA technology is growing at the highest CAGR in the Mycoplasma Testing Market due to its high throughput, cost-effectiveness, and ease of use. ELISA assays provide reliable and accurate detection of mycoplasma contamination with a relatively straightforward procedure, making it suitable for routine testing in various settings. Advances in ELISA technology, including improved sensitivity and automation, enhance its appeal. The increasing adoption of ELISA for quality control in biopharmaceutical production contributes significantly to its rapid growth.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Mycoplasma Testing Application Segment Analysis

Mycoplasma Testing Market Application Segment Analysis

According to Cognitive Market Research, the dominant category is Cell Line Testing. Cell Line Testing holds the largest market share in the Mycoplasma Testing Market due to its critical role in ensuring the integrity and safety of biopharmaceuticals and research. Cell lines are widely used in drug development, production of biologics, and research, making it essential to detect and prevent mycoplasma contamination to maintain product quality. The high demand for reliable and contamination-free cell cultures in various applications drives the dominance of cell line testing in the market.

Virus Testing is growing at the highest CAGR in the Mycoplasma Testing Market due to increasing concerns over viral contamination in biopharmaceuticals and cell-based therapies. The rising complexity of viral assays and the need for rigorous quality control in vaccine and biologic production drive this growth. Advances in testing technologies and heightened regulatory scrutiny further contribute to the rapid expansion of virus testing applications, ensuring the safety and efficacy of critical therapeutic products.

• Cell Line Testing
• Virus Testing
• End of Production Cells Testing
• Others

Mycoplasma Testing End User Segment Analysis

Mycoplasma Testing Market End User Segment Analysis

According to Cognitive Market Research, the dominant category is Academic Research Institutes. Academic Research Institutes capture the largest market share in the Mycoplasma Testing Market due to their extensive use of cell cultures and laboratory testing for research and development. These institutes require reliable mycoplasma detection to ensure the accuracy and validity of their scientific studies. The high volume of research activities, coupled with the need for rigorous quality control and contamination prevention in experiments, drives the dominance of academic research institutes as key end users in the market.

Cell Banks are growing at the highest CAGR in the Mycoplasma Testing Market due to their critical role in storing and supplying cell lines for biopharmaceutical production and research. As demand for biologics and cell-based therapies increases, maintaining contamination-free cell banks is essential. The need for rigorous quality control to ensure the safety and efficacy of stored cells drives the rapid growth in testing services for cell banks, ensuring compliance with regulatory standards and maintaining product integrity.

• Academic Research Institutes
• Cell Banks
• Contract Research Organizations
• Pharmaceutical and Biotechnology Companies
• Others

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion